Company patents
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. demonstrates a focused patent strategy, with over 65% of its portfolio in Pharmaceutical Preparations (77 patents) and nearly 60% in Heterocyclic Compounds (Pharma) (70 patents), indicating a strong emphasis on drug discovery and development. While patenting in Therapeutic Activity (Pharma) saw a significant 100.0% increase in 2025, the overall trend for 2026 so far shows a notable decline across its top categories, with Pharmaceutical Preparations down 52.2% and Heterocyclic Compounds (Pharma) down 28.6% year-over-year, suggesting a potential shift in patenting pace or focus.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
118 US filings (since 2023) · 5 categories · 6 themes
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Patents
Showing 1-10 of 140